Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521
Christian Skorik, Nathaniel K. Mullin, Michael Shi, Yosra Zhang, Phoebe Hunter, Yang Tang, Brianna Hilton, Thorsten M. Schlaeger
下载PDF
{"title":"Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521","authors":"Christian Skorik, Nathaniel K. Mullin, Michael Shi, Yosra Zhang, Phoebe Hunter, Yang Tang, Brianna Hilton, Thorsten M. Schlaeger","doi":"10.1002/cpsc.103","DOIUrl":null,"url":null,"abstract":"<p>Translating human induced pluripotent stem cell (hiPSC)–derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component–free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component–free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent–derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages. © 2020 by John Wiley & Sons, Inc.</p><p><b>Basic Protocol 1</b>: Isolating peripheral blood mononuclear cells using CPT tubes</p><p><b>Support Protocol 1</b>: Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1</p><p><b>Basic Protocol 2</b>: PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum</p><p><b>Basic Protocol 3</b>: Reprogramming of expanded PBMCs with Sendai viral reprogramming particles</p><p><b>Alternate Protocol</b>: Reprogramming of expanded PBMCs with episomal plasmids</p><p><b>Basic Protocol 4</b>: Picking, expanding, and cryopreserving hiPSC clones</p><p><b>Support Protocol 2</b>: Testing Sendai virus kit–reprogrammed hiPSC for absence of Sendai viral RNA</p><p><b>Support Protocol 3</b>: Testing Epi5 kit–reprogrammed hiPSC for absence of episomal plasmid DNA</p><p><b>Support Protocol 4</b>: Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging</p><p><b>Support Protocol 5</b>: Coating plates with extracellular matrices to support hiPSC attachment and expansion</p>","PeriodicalId":53703,"journal":{"name":"Current Protocols in Stem Cell Biology","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpsc.103","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Stem Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpsc.103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 3
引用
批量引用
Abstract
Translating human induced pluripotent stem cell (hiPSC)–derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component–free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component–free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent–derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages. © 2020 by John Wiley & Sons, Inc.
Basic Protocol 1 : Isolating peripheral blood mononuclear cells using CPT tubes
Support Protocol 1 : Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1
Basic Protocol 2 : PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum
Basic Protocol 3 : Reprogramming of expanded PBMCs with Sendai viral reprogramming particles
Alternate Protocol : Reprogramming of expanded PBMCs with episomal plasmids
Basic Protocol 4 : Picking, expanding, and cryopreserving hiPSC clones
Support Protocol 2 : Testing Sendai virus kit–reprogrammed hiPSC for absence of Sendai viral RNA
Support Protocol 3 : Testing Epi5 kit–reprogrammed hiPSC for absence of episomal plasmid DNA
Support Protocol 4 : Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging
Support Protocol 5 : Coating plates with extracellular matrices to support hiPSC attachment and expansion
外周血单核红母细胞对层粘连蛋白521的无xeno重编程
将人类诱导多能干细胞(hiPSC)衍生的细胞和组织转化为临床需要简化和可靠的生产临床级hiPSC。本文描述了一种完全不含动物成分的方法,该方法仅使用自体患者材料和无xeno试剂,从供体外周血单个核细胞(PBMCs)中可靠地衍生出稳定的hiPSC系。pbmc是从捐献的全血中分离出来的,从全血中也可以产生少量的患者血清。然后将pbmc扩增,然后在补充自体患者血清的无动物成分红母细胞生长培养基中进行重编程,从而消除了对动物血清的需求。扩增后,使用cgmp级仙台病毒颗粒(CytoTune™2.1试剂盒)或episally复制重编程质粒(Epi5™试剂盒)对红母细胞进行重编程,这两种方法都是市购的。在重组cgmp级人层粘连蛋白底物上扩增新出现的hipsc与许多无xeno或化学定义的培养基(一些可作为cgmp级试剂)兼容,例如E8, Nutristem, Stemfit或mTeSR Plus。使用这种方法获得的hiPSC细胞系显示出预期的表面标记和转录因子的表达,失去了重编程剂衍生的核酸,遗传稳定性以及在体外向多个谱系分化的能力。©2020 by John Wiley &基本方案1:使用CPT管分离外周血单个核细胞支持方案1:从收集的自体血浆中去除凝血因子产生血清基本方案1基本方案2:在含自体血清的无动物红细胞扩增培养基中扩增PBMC基本方案3:用仙台病毒重编程颗粒对扩增的PBMC进行重编程备用方案:用外生质粒对扩增的PBMC进行重编程基本方案4:提取、扩增和冷冻保存hiPSC克隆支持方案2:检测仙台病毒试剂盒-重编程的hiPSC是否缺乏仙台病毒rnassupport方案3:检测Epi5试剂盒-重编程的hiPSC是否缺乏episomal质粒dna nassupport方案4:通过多色免疫荧光染色和共聚焦成像评估人类多能干细胞培养的未分化状态支持方案5:用细胞外基质涂膜板支持hiPSC附着和扩增
本文章由计算机程序翻译,如有差异,请以英文原文为准。